Description
Filstim (Filgrastim) Solution for Injections 1.6 ml (48 ml n IU) 0.48 mg №1 Syringe
Ingredients:
Each 1.6 ml syringe contains 0.48 mg of Filgrastim.
Mechanism of Action:
Filgrastim stimulates the production of white blood cells in the body, aiding in the prevention of infections, particularly in patients undergoing chemotherapy or bone marrow transplants.
Pharmacological Properties:
Filgrastim, a granulocyte colony-stimulating factor (G-CSF), acts on hematopoietic cells to increase the production and differentiation of neutrophils, enhancing the body’s immune response.
Indications for Use:
Filstim is indicated for the treatment of neutropenia, characterized by abnormally low levels of neutrophils. It is commonly employed in cancer patients undergoing chemotherapy to reduce the risk of infections.
Contraindications:
Avoid using Filstim if there is a known hypersensitivity to Filgrastim or any components of the product. Patients should consult their healthcare provider regarding any underlying medical conditions before initiating treatment.
Side Effects:
Common side effects of Filstim may include bone pain, fever, and injection site reactions. In rare cases, serious allergic reactions can occur. Patients should seek immediate medical attention if any severe side effects manifest.
Usage Instructions:
The administration of Filstim should be as directed by a healthcare professional, often via subcutaneous injection. Proper disposal of syringes and needles following use is crucial to adhere to medical waste disposal protocols.
Benefits Compared to Analogues:
Filstim offers a distinct advantage over analogues by effectively reducing the incidence of febrile neutropenia and hospitalizations due to infections in cancer patients, as supported by clinical evidence.
Suitable Patient Groups:
Filstim is suitable for various patient populations, including children and the elderly, under the supervision of a qualified healthcare provider.
Storage and Shelf Life:
It is imperative to store Filstim as per the instructions provided and ensure it is inaccessible to children. Adherence to proper storage conditions preserves the medication’s efficacy throughout its shelf life.
Packaging Description:
Filstim is available in a 1.6 ml syringe presentation, each containing 0.48 mg of Filgrastim, providing a convenient and accurate dosing option for patients.
Scientific Evidence:
Research studies have demonstrated the efficacy of Filgrastim in reducing febrile neutropenia incidence and the need for hospitalization due to infections in cancer patients, highlighting its clinical utility.
Additional Information:
For further details on Filstim usage and to address any queries or concerns, patients are advised to consult their healthcare provider. In case of severe side effects or allergic reactions, immediate medical assistance should be sought.
